A comparative study with 7,893 HFrEF patients focused on the fact that sacubitril-valsartan reduced risks of death and hospitalization for HF (HR = 0.8) compared to enalapril in ambulatory patients with HFrEF in the PARADIGM-HF trial. They concluded that in a heterogeneous cohort of patients with systolic HF (the mean follow-up time was 6.3 months), sacubitril-valsartan was associated with a reduced risk of death and hospitalization compared with ACE/ARB. The gene discussed is ACE; the disease is hydrops fetalis.